Questions: Asthma: Airway Inflammation and Reversible Obstruction

Question 1

A 26-year-old with asthma uses her short-acting bronchodilator 5 times per week and reports feeling 'well-controlled' because her symptoms always resolve quickly. She has not used inhaled corticosteroids. Which statement best characterizes her clinical situation?

• A. She is well-controlled; symptom resolution with a bronchodilator is the standard measure of asthma control
• B. She is undertreated: frequent bronchodilator use controls bronchoconstriction but leaves the underlying Type 2 inflammation unaddressed, allowing progressive airway remodeling
• C. She needs a longer-acting bronchodilator, not an anti-inflammatory agent
• D. Her frequency of rescue inhaler use is within normal limits and requires no change in management

Answer: (B)

This scenario captures the core clinical misconception. Bronchodilators relax airway smooth muscle and reverse acute bronchoconstriction — they address the symptom. They do not reduce eosinophilic inflammation, mast cell activation, or the ongoing Type 2 immune response. Without inhaled corticosteroids targeting the inflammatory process, subepithelial fibrosis and smooth muscle hypertrophy accumulate silently between symptomatic episodes. Five rescue inhaler uses per week itself signals poorly controlled disease, regardless of symptom resolution.

Question 2

A patient with a 15-year history of severe, untreated asthma undergoes spirometry showing a reduced FEV1/FVC ratio that does not normalize after bronchodilator administration. Which pathological process best explains this fixed obstruction?

• A. Acute mast cell degranulation causing irreversible smooth muscle contraction
• B. Airway remodeling — subepithelial fibrosis, smooth muscle hypertrophy, and increased vascularity — that permanently reduces airway caliber
• C. Mucus plugging from goblet cell hyperplasia blocking the lumen at the time of testing
• D. Eosinophilic inflammation causing transient epithelial swelling that is steroid-responsive

Answer: (B)

The term 'reversible obstruction' in asthma refers only to the acute bronchoconstriction that responds to bronchodilators. Chronic, uncontrolled inflammation produces structural changes — subepithelial collagen deposition, smooth muscle cell hypertrophy, neovascularization — that are not reversed by bronchodilators or even steroids once established. This is why persistent asthma can produce a COPD-like fixed obstruction pattern, and why anti-inflammatory therapy early in the disease course is preventive as well as therapeutic.

Question 3

Asthma is correctly described as 'reversible airway obstruction' because bronchoconstriction generally resolves mostly with bronchodilator treatment, and long-term lung function is not compromised.

• T. True
• F. False

Answer: False

This is a common misconception. 'Reversible' describes the acute bronchoconstriction that responds to beta-agonists — not the long-term trajectory of the disease. Chronic, inadequately treated asthma leads to airway remodeling: subepithelial fibrosis, smooth muscle hypertrophy, and goblet cell metaplasia. These structural changes produce fixed airflow limitation that does not reverse with bronchodilators and can resemble COPD. The name 'reversible obstruction' reflects the acute physiology, not the guarantees of long-term outcome.

Question 4

Bronchial hyperresponsiveness in asthma — the tendency to bronchoconstrict in response to cold air, exercise, and irritants — results from chronic airway inflammation lowering the threshold for smooth muscle contraction, not from an intrinsic defect the patient was born with.

• T. True
• F. False

Answer: True

Correct. The inflamed, edematous airway develops altered smooth muscle reactivity through several mechanisms: smooth muscle hypertrophy from repeated activation, sensory nerve hyperexcitability from inflammatory mediator exposure, and impaired neural regulation. These changes lower the threshold for bronchoconstriction so far that stimuli innocuous to healthy airways trigger significant obstruction. The degree of hyperresponsiveness — measurable by methacholine challenge — correlates with underlying inflammation severity and improves with anti-inflammatory treatment.

Question 5

Explain why relying solely on a short-acting bronchodilator for asthma management, while effective at relieving symptoms, is considered inadequate and potentially harmful long-term treatment.

Model answer: Bronchodilators reverse acute bronchoconstriction by relaxing airway smooth muscle, but they do not address the underlying Type 2 inflammatory process (Th2 cells, IL-4, IL-5, mast cell activation, eosinophil infiltration). Inflammation persists between symptomatic episodes, driving ongoing epithelial damage and structural remodeling. Over time, this produces subepithelial fibrosis and smooth muscle hypertrophy that permanently reduce airway caliber — changes that cannot be reversed once established. Inhaled corticosteroids target the inflammatory process and prevent remodeling; bronchodilators treat only the downstream symptom.

The key distinction is mechanism vs. manifestation. Bronchoconstriction is the manifestation; Type 2 inflammation is the mechanism. Treating only the manifestation is like treating the smoke without the fire.